HYDERABAD, India — Dr. Reddy’s Laboratories has launched rivastigmine tartrate capsules, a treatment for dementia caused by Alzheimer’s or Parkinson’s disease, in the U.S. market.
The pharmaceutical company said Thursday that its rivastigmine tartrate capsules are available in strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg and come in 60-count bottles.
According to Dr. Reddy’s, the Food and Drug Administration-approved product is a bioequivalent generic version of Novartis’ Exelon capsules.
U.S. sales of Exelon brand and generic rivastigmine tartrate capsules totaled approximately $92.6 million for the 12 months ended June 2011, according to IMS Health data cited by Dr. Reddy’s.
